Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom

a technology of phenylene and diamine, which is applied in the field of medical technology, can solve the problems of poor effect of the second-generation inhibitor on drug resistant patients and no drugs available for them

Active Publication Date: 2017-01-12
SHANGHAI HAIYAN PHARMA TECH +1
View PDF0 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes compounds that can specifically inhibit a mutated form of EGFR (EGFR T790M) but have low activity against the wild-type form of EGFR. This creates a high selective inhibition for the mutant enzyme and cells. Additionally, these compounds have low non-specific cytotoxicity, which makes them safer for use.

Problems solved by technology

However, most of patients acquire resistance in 6-12 months, the first generation of EGFR inhibitors will no longer take effect, and currently no drugs are available for these patients.
However, the second-generation of inhibitors also have strong inhibitory activity for wild-type EGFR, and the inhibitory activity for wild-type EGFR was significantly higher than that for resistant T790M mutation, and side effects, such as skin rashes, were severe in patients, and the effect of the second-generation of inhibitors on drug resistant patients was poor, only a small part of patients who are resistant to the first generation of EGFR inhibitors response to these drugs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
  • 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
  • 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom

Examples

Experimental program
Comparison scheme
Effect test

example 1

N-(5-(5-chloro-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-2-amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)acrylamide (compound Z-1)

[0149]

Step 1

5-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridine (Compound 1-2)

[0150]At 0° C., a solution of compound 5-bromo-1H-pyrrolo[2,3-b]pyridine (5 g, 25.4 mmol, commercially available) in DMF was added to a solution of sodium hydride (4.32 g, 30.5 mmol) in 40 ml of DMF, and vigorously stirred at 0° C. for 0.5 h, and then methyl iodide (1.22 g, 30.5 mmol) was added, and stirred vigorously at room temperature for 3 h. The reaction progress was monitored by TLC. After completion of the reaction, the reaction solution was poured into ice water. After the solids were completely precipitated, the solids were filtered and dissolved in dichloromethane and methanol (10:1), washed with water three times, and dried. The organic layer was separated, and concentrated under reduced pressure to give compound 1-2 (5.4 g, 99%). The product was use...

example 2

N-(5-(5-chloro-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-2-amino)-2-(4-(dimethylamino)piperidin-1-yl)-4-methoxyphenyl)acrylamide (compound Z-2)

[0157]

Step 1

5-chloro-N-(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-2-amine (compound 2-6)

[0158]Compound 1-5 (260 mg, 0.607 mmol) and potassium carbonate (251 mg, 1.822 mmol) were added into a 25 ml reaction flask, DMF (10 mL) was added to partially dissolve the substrate, and then N,N-dimethylamino piperidine (85.4 mg, 0.667 mmol) was added, and the reaction system was maintained at 70° C. for 3 h. The reaction progress was monitored by TLC. After completion of the reaction, the reaction solution was extracted with EA / water system for three times, and the organic layer was separated, washed with water, saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to give the crude compound 2-6, 220 mg, yield 68%. MS M / Z (ESI) 537.2[M+H]+.

St...

example 3

N-(5-(5-chloro-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-2-amino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamide (compound Z-3)

[0161]

Step 1

5-chloro-N-(2-methoxy-4-(4-methylpiperazin-1-yl)-5-nitrophenyl)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-2-amine (compound 3-6)

[0162]N-methylpiperazine (126 mg, 1.26 mmol) and potassium carbonate (261 mg, 1.89 mmol) were added to a solution of compound 1-5 (200 mg, 0.47 mmol) in 4 ml of DMF, and vigorously stirred at 100° C. for 2 h. The reaction progress was monitored by TLC. After completion of the reaction, 10 ml of water was added, extracted with EA / water system for three times, and the organic layer was separated, and concentrated under reduced pressure to give compound 3-6 (200 mg, 84%). MS m / z (ESI): 509.2[M+H]+.

Step 2

N1-(5-chloro-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-2-yl)-6-methoxy-4-(4-methylpiperazin-1-yl)benzene-1,3-diamine (compound 3-7)

[0163]By using compound 3-6 (200 mg, 0.39 mmol) as the s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Electrical resistanceaaaaaaaaaa
Login to View More

Abstract

The present invention provides a class of 2,4-substituted phenylene-1,5-diamine derivatives, having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvate or prodrug of said derivatives. See the description for the definition of each group in the formula. In addition, the present invention also discloses pharmaceutical compositions, pharmaceutically acceptable compositions and applications thereof.

Description

TECHNICAL FIELD[0001]The present invention relates to the field of medical technology, particularly to a 2,4-disubstituted benzene-1,5-diamine derivatives and uses thereof as EGFR tyrosine kinase inhibitors, and pharmaceutical compositions and medicinal compositions prepared therefrom.BACKGROUND[0002]Lung cancer is of the highest incidence in the world. In China, the incidence of lung cancer ranks first among all cancers, and the incidence and mortality rates of the cancer are also the highest in China. In the lung cancer patients in China, 30% of patients have EGFR mutations, over 90% of which are L858R and exon 19 deletion mutation, and these patients are more sensitive to EGFR inhibitors. The marketed first-generation of EGFR inhibitors, such as erlotinib, gefitinib have good effect for these patients, and the tumor in more than 60% of patients will shrink, significantly prolonging the progression-free survival of patients. However, most of patients acquire resistance in 6-12 mon...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D471/04C07D401/12A61K31/5377C07D491/08C07D401/14C07D401/04A61K31/53A61K31/553A61K31/506C07D239/48
CPCC07D471/04A61K31/506C07D401/12A61K31/5377C07D239/48C07D401/14C07D401/04A61K31/53A61K31/553C07D491/08C07D403/04C07D413/04C07D413/14A61K31/5386A61K45/06A61P25/28A61P35/00A61P37/02A61P43/00A61P9/00A61P3/10A61K2300/00A61K31/56C07D403/12C07D403/14
Inventor LAN, JIONGJIN, YUNZHOUZHOU, FUSHENGXIE, JINGSHEN, SIDAHU, YILIU, WEILV, QIANG
Owner SHANGHAI HAIYAN PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com